PEPID Pulse
  • Blog
  • Alerts
  • Press
  • pepid.com
Select Page
First P13K inhibitor for Breast Cancer Gets FDA Approved

First P13K inhibitor for Breast Cancer Gets FDA Approved

by PEPID Newsroom | May 24, 2019 | Alerts

Pigray (alpelisib) tablets have been FDA approved to treat breast cancer in combination with FDA-approved endocrine therapy fulvestrant. Pigray is approved for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2...
Breakthrough Non-Drug ADHD Treatment Gets FDA Approval

Breakthrough Non-Drug ADHD Treatment Gets FDA Approval

by PEPID Newsroom | Apr 19, 2019 | Alerts

Children living with attention hyperactivity disorder (ADHD) may soon experience non-pharmacologic relief through a breakthrough medical device. For children between the ages 7 and 12 and currently not on medication, the pocket-sized device works by delivering mild...

FDA Approves a New Generic Valsartan to Mitigate Shortages

by PEPID Newsroom | Mar 14, 2019 | Alerts

As of March 12, 2019 the U.S. FDA approved a new generic of Diovan (valsartan) for high blood pressure and heart failure to relieve the shortage from multiple recalls of generic valsartan products from several manufacturers. The approval of the new generic of Diovan...

Recent Posts

  • What Is a DNP? Everything You Need to Know About the Doctor of Nursing Practice
  • Halloween Health & Safety: Tips for Families and Clinicians
  • Exploring a Career in Nursing: What You Need to Know
  • Back-to-School Wellness — A Resource for Families and Providers
  • The Summer Injury Spike: Common ER Visits and How to Prevent Them

Categories

  • Alerts
  • Emergency Medicine
  • Featured Posts
  • Nursing
  • Pharmacy
  • Press & Media
  • Primary Care
  • Uncategorized
PEPID, LLC. All rights reserved